Clinical trials
Completed Phase 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 11 |
| Medical College of Wisconsin | 3 |
| Fred Hutchinson Cancer Center | 2 |
| Novartis | 2 |
| Pfizer | 2 |
| St. Jude Children's Research Hospital | 2 |
| University of Jena | 2 |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 1 |
| Bristol-Myers Squibb | 1 |
| Case Comprehensive Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 42 |
| Leukemia | 12 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 |
| Leukemia, Myeloid, Acute | 9 |
| Myelodysplastic Syndromes | 9 |
| Leukemia, Myeloid, Chronic-Phase | 5 |
| Lymphoma | 5 |
| Hodgkin Disease | 4 |
| Lymphoma, Non-Hodgkin | 4 |
| Bone Marrow Diseases | 3 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.